Passive antibody therapy in COVID-19

For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated...

Descripción completa

Detalles Bibliográficos
Autor principal: Abraham, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290146/
https://www.ncbi.nlm.nih.gov/pubmed/32533109
http://dx.doi.org/10.1038/s41577-020-0365-7
_version_ 1783545608209956864
author Abraham, Jonathan
author_facet Abraham, Jonathan
author_sort Abraham, Jonathan
collection PubMed
description For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered offers an attractive alternative option for passive immunization.
format Online
Article
Text
id pubmed-7290146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72901462020-06-12 Passive antibody therapy in COVID-19 Abraham, Jonathan Nat Rev Immunol Comment For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS-CoV-2 vaccines to be tested and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered offers an attractive alternative option for passive immunization. Nature Publishing Group UK 2020-06-12 2020 /pmc/articles/PMC7290146/ /pubmed/32533109 http://dx.doi.org/10.1038/s41577-020-0365-7 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Abraham, Jonathan
Passive antibody therapy in COVID-19
title Passive antibody therapy in COVID-19
title_full Passive antibody therapy in COVID-19
title_fullStr Passive antibody therapy in COVID-19
title_full_unstemmed Passive antibody therapy in COVID-19
title_short Passive antibody therapy in COVID-19
title_sort passive antibody therapy in covid-19
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290146/
https://www.ncbi.nlm.nih.gov/pubmed/32533109
http://dx.doi.org/10.1038/s41577-020-0365-7
work_keys_str_mv AT abrahamjonathan passiveantibodytherapyincovid19

Ejemplares similares